HLA-B*5701 screening

Testing for HLA-B*5701 status should be considered before initiating abacavir treatment.

Screening is also recommended prior to re-initiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.

HLA-B*5701 status must always be documented and explained to the patient prior to initiating therapy.

In HLA-B*5701–negative patients, clinical vigilance remains vital to detect any abacavir hypersensitivity at the earliest stage.

Results of pharmacogenetic tests for risk of abacavir hypersensitivity should never be used to support a drug rechallenge decision after a suspected hypersensitivity reaction.

HLA-B*5701 testing must not be used as a diagnostic test after a patient has started treatment with abacavir.